Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)
Agilent Technologies, Inc. (A)
Last agilent technologies, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.agilent.com
Company Research
Source: Business Wire
Companion diagnostic can help guide treatment decisions in cases of NSCLC SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC). PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) = 50% for treatment with Libtayo® (cemiplimab-rwlc). This announcement underscores Agilent's continuing commitment to the development of IHC-based diagnostics for cancer therapy.Lung cancer is the leading cause of cancer death in both men and women in the United States, with NSCLC making up 85% of all lung cancer cases.1,2 PD-L1 expression is a biomarker for response to anti-PD-1 therapy in NSCLC; this expanded indication enables pathologists to identify patients with advanced NSCLC who may be eligible for treatm
Show less
Read more
Impact Snapshot
Event Time:
A
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
A alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
A alerts
High impacting Agilent Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
A
News
- High-Performance Liquid Chromatography Market - A Global and Regional Analysis (2023-2033): Focus on Application, Product, Region, and Competitive Landscape [Yahoo! Finance]Yahoo! Finance
- Global RNA Analysis Market Forecast, 2028: Rising RNA-Seq Data Volume Spurs Demand for Advanced Bioinformatics Tools, Enhanced Algorithms Key in Harnessing Genetic Insights [Yahoo! Finance]Yahoo! Finance
- microRNA (miRNA) Global Strategic Business Report 2024-2030: Increasing Investments and Focus on Development of miRNA-based Therapeutics Bodes Well for Market Growth [Yahoo! Finance]Yahoo! Finance
- Agilent Technologies' (NYSE:A) earnings growth rate lags the 13% CAGR delivered to shareholders [Yahoo! Finance]Yahoo! Finance
- Laser Capture Microdissection (LCM) Market Size Expected to Reach USD 397.74 Million By 2032, at 10.1% CAGR Growth: Polaris Market Research [Yahoo! Finance]Yahoo! Finance
A
Earnings
- 2/27/24 - Beat
A
Sec Filings
- 4/10/24 - Form SC
- 3/27/24 - Form 4
- 3/25/24 - Form 144
- A's page on the SEC website